Lupus

Although commonly referred to as an “invisible illness,” lupus — and some of its treatments — can manifest in ways that are not only visible, but also heavily impact the daily lives of patients.

DESTIN, Fla. — Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Systemic lupus erythematosus may benefit from being redefined and further subdivided, depending on the autoantibody profile of the patient, according to a speaker at the Congress of Clinical Rheumatology East 2022.

DESTIN, Fla. — Nephritis and phospholipid antibodies should be considered as contributors to cardiovascular disease risk in patients with systemic lupus erythematosus, according to a speaker at the Congress of Clinical Rheumatology East.

Although patients with lupus nephritis may require prednisone maintenance, attempts should be made to reduce their steroid doses, said a speaker at The Future of Systemic Lupus Erythematosus Diagnosis and Treatment meeting.

People of color with lupus are more likely to experience delayed diagnosis along with greater rates of morbidity and mortality, compared with white patients, according to data.

Children and adolescents with rheumatic and musculoskeletal diseases who contract COVID-19 are not likely to require hospitalization, according to data published in the Annals of the Rheumatic Diseases.

Researchers found that long-term remission of cutaneous lupus erythematosus occurred in nearly 20% of patients, according to a study published in the Journal of American Academy of Dermatology.

The first proposed definition for disease modification in systemic lupus erythematosus, including lupus nephritis, requires “minimizing” disease activity with few treatment-associated toxicities, while slowing organ damage progression.

Iberdomide, a novel oral cereblon modulator, was superior to a placebo only in patients with systemic lupus erythematosus who received the highest dose in a phase 2 trial, albeit with a high incidence of adverse events, according to data.